In The News
Genetic Engineering & Biotechnology News | January 15, 2018
New technology has shown promise for detecting CTE and the approximately 150 protein biomarkers linked to conditions in neurology, oncology, cardiology, inflammation, and infectious disease. Called Simoa™, it is a single-molecule array on a fully automated digital immunoassay platform that detects…
January 12, 2018
Presentation led by Kevin Hrusovsky, President, Chairman and CEO Quanterix Presentation Date: Wednesday, January 10, 2018
Bloomberg Baystate Business | December 08, 2017
Bloomberg Boston Bureau Chief Tom Moroney and Radio News Anchor Anne Mostue are joined by Quanterix CEO Kevin Hrusovsky to discuss his company’s IPO and first day of trading
The Wall Street Journal | December 08, 2017
Biomarker-analysis company had raised venture capital from ARCH Venture Partners, Bain
Cheddar.com | December 08, 2017
Quanterix, a company developing technology designed to enable earlier disease detection, made its market debut on Thursday. Shares of the company surged after pricing at $15 a share, and opening at $16.25 a share.
The Scientist | December 01, 2017
# 5 Quanterix | SR-X Ultra-Sensitive Biomarker Detection System
SelectScience | November 30, 2017
Kevin Hrusovsky is President and CEO of Quanterix, a company that is developing an ultrasensitive immunoassay platform that is capable of detecting very low levels of biomarkers in the body. Watch this exclusive interview to discover Hrusovsky’s vision for the future of healthcare.
Alzforum | November 17, 2017
Serum NfL levels rise before symptoms appear in familial AD. NfL correlates with cognitive decline and brain atrophy. In MS patients, NfL levels drop with treatment.
May 13, 2008
Read the article at www.technologyreview.com